Navigation Links
OrbusNeich's Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up
Date:5/15/2012

PARIS, May 15, 2012 /PRNewswire/ -- OrbusNeich today announced that 12-month follow-up data from the REMEDEE study showed favorable clinical and safety outcomes involving the use of the company's Combo Dual Therapy Stent when compared to the TAXUS® Liberte® paclitaxel-eluting stent. The data were presented by Michael Haude, M.D., of Medical Clinic I at the Lukaskrankenhaus in Neuss, Germany, at EuroPCR 2012.

In the 12-month follow-up data set, the clinically driven target lesion failure (TLF) rate was 8.9% for patients treated with the Combo Stent, compared to 10.2% for those treated with the TAXUS stent. Clinically driven TLF was defined as a composite of death, myocardial infarction (MI) and clinically driven target lesion revascularization (TLR). In addition, the rate of clinically driven TLR was 4.9% for patients treated with the Combo Stent, compared to 8.5% for those treated with the TAXUS stent. There was no stent thrombosis (ST) in either of the groups.

"The in-stent and in-segment late loss and binary restenosis rates were accordingly low for the Combo Stent and comparable to those of the TAXUS stent," said Prof. Haude. "Additionally, we saw a uniform, homogeneous neointimal response with the Combo Stent, compared to the more heterogeneous and layered neointimal tissue appearance with the TAXUS stent. Other data are being presented this week, and we look forward to presenting two-year follow-up and other results of the REMEDEE study at upcoming conferences."

REMEDEE (Randomized Evaluation of an abluMinal sirolimus coatED bio-Engineered stEnt) is a randomized clinical trial designed to demonstrate the safety and efficacy of the Combo Dual Therapy Stent compared to the TAXUS stent in patients with symptomatic, ischemic heart disease due to a stenotic lesion located in a native coronary artery. The study's primary en
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Data From REMEDEE Trial Featuring OrbusNeichs Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011
2. Combo method reveals cells signal systems
3. Computer-designed molecules point to new therapy for cystic fibrosis
4. Radiotherapy Clinics of Georgias Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award
5. Valkee and University of Oulu Publish the First Clinical Trial on Bright Light Therapy Channeled via ear Canals in Seasonal Depression
6. Cell Therapy - Technologies, Markets and Companies
7. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
8. Gene therapy research from Penn Vet & Scheie Eye Inst. cures retinitis pigmentosa in dogs
9. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
10. Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board
11. Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 CORD:USE Cord Blood Bank – ... it has entered into an Equity and Exclusive Services ... licensed a series of patented technologies for the isolation of ... applications.  Tianhe is performing Phase I/II clinical trials in ... using Tianhe,s Stem Cell Educator Therapy showing ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 ... solutions for drug discovery and related life ... consortium has chosen Genedata Selector as its ... (NGS) data. FUNGITECT is a European consortium ... fungal diseases via individualized anti-fungal drug therapies. ...
(Date:9/30/2014)... , Sept. 30, 2014  KemPharm, Inc., ... discovery and development of proprietary new molecular entity ... Patent and Trademark Office (USPTO) issued U.S. Patent ... entitled, "Benzoic Acid, Benzoic Acid Derivatives and Heteroaryl ... Making and Use Thereof." The patent, ...
(Date:9/30/2014)... , Sept. 30, 2014 FemCap Inc., ... health announces its receipt of a patent No: US, ... cup has also received FDA clearance in the U.S., ... the CE in Europe. This patent is related to its ... this issuance, the company is releasing FemmyCycle Teen, a ...
Breaking Biology Technology:CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2The FemmyCycle 2
... Beckman Coulter,Inc. (NYSE: BEC ), a ... automate, and innovate complex biomedical testing,announced today that ... present at the 19th Annual Piper Jaffray Healthcare,Conference ... (ET). (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ) The ...
... Highlighted by the,introduction of the IQQA(R) Enterprise ... radiology imaging market with its universal enterprise,solution, ... of 2D/3D/4D advanced,clinical applications on existing PACS ... code-level integration. Available on the,IQQA(R) Enterprise Engine ...
... Saint Louis University,(SLU) recognized St. Louis-based Sigma-Aldrich(TM) (Nasdaq: ... life science and high technology company,s,recent $1 million ... largest,in Sigma-Aldrich history, comes in the form of ... by the university,s medical school research,teams. (Photo: ...
Cached Biology Technology:Beckman Coulter to Present at the 19th Annual Piper Jaffray Healthcare Conference 2EDDA Technology Introduces Universal Enterprise Solution - Enabling 2D/3D/4D Advanced Clinical Applications on Existing PACS Workstations 2EDDA Technology Introduces Universal Enterprise Solution - Enabling 2D/3D/4D Advanced Clinical Applications on Existing PACS Workstations 3Saint Louis University Honors Sigma-Aldrich Corp. for $1 Million Donation 2
(Date:9/30/2014)... Here,s some hope: A new research report published in ... , explains how scientists developed a synthetic version ... embryo development in human and mouse eggs similar to ... cell during fertilization. , "We believe that the results ... our understanding of human fertilization by providing a precise ...
(Date:9/30/2014)... 30, 2014  Spectra Automation, a trusted ... biotech and power generation industries, announced today ... Manager, an easy-to-use and cost-effective data collection, ... development laboratories. Most upstream ... analyzer systems. Accessing and consolidating data from ...
(Date:9/30/2014)... 30, 2014) People who suffer from asthma may ... control their asthma besides properly taking medications and avoiding ... in the Annals of Allergy, Asthma and Immunology ... Allergy, Asthma and Immunology (ACAAI), asthma sufferers can learn ... The woman described in the Annals article improved her ...
Breaking Biology News(10 mins):Synthetic sperm protein raises the chance for successful in vitro fertilization 2Spectra Automation Introduces RECONN Bioprocess Manager 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... A new study, supported in part by the National Heart, ... Health, suggests that a combination of mobile technology and remote ... behavior in adults. The study focused on the best way ... appear Monday, May 28, in the Archives of Internal ...
... A study led by researchers from McGill University provides ... heart a finding that promises to contribute to the ... heart tissue. The research, published in the Proceedings ... the muscle fibers in the heart wall are locally arranged ...
... getting stronger or weaker? Right now, it,s hard to know. ... this medical challenge by developing and applying a technique that ... technique was more sensitive in detecting bone loss than the ... it may find use in clinical settings, and could pave ...
Cached Biology News:NIH-funded study examines use of mobile technology to improve diet and physical activity behavior 2Study provides new insights into structure of heart muscle fibers 2Earlier detection of bone loss may be in future 2Earlier detection of bone loss may be in future 3Earlier detection of bone loss may be in future 4
... units/µL ,• High specific activity and processivity ... 'A' overhang ,• Processes ,A ... activity in primer extension and other molecular ... the enzyme, each lot has been functionally ...
... Recombinant DNA polymerase from Thermus aquaticus ... DNA contamination; 1 tube of 250 units ... LD (Low DNA), is the same enzyme ... purified through a proprietary separation process to ...
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
Taq DNA polymerase, 10,000U...
Biology Products: